Dialysate and plasma meropenem concentrations in continuous intraperitoneal regimen during peritoneal-dialysis-related peritonitis
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0312160 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Thatsaphan Srithongkul und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Meropenem, Peritonitis, Peritoneal Dialysis, Dialysis Solutions. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A single dose of intraperitoneal (IP) meropenem is recommended for peritoneal-dialysis (PD)-related peritonitis stemming from extended-spectrum β-lactamase-producing organisms. However, data on IP meropenem is limited.
Methods
This prospective, descriptive study was conducted to examine plasma and dialysate meropenem levels during continuous IP meropenem administration in five patients with PD-related peritonitis. All patients received an IP meropenem loading dose of 500 mg, followed by IP meropenem at 125 mg/L, with four exchanges daily. The plasma and dialysate meropenem concentrations were measured at specified intervals for a 24-hour period utilizing a high-performance, liquid chromatography method.
Results
Five patients with PD related peritonitis were studied. The mean-maximum dialysate and plasma meropenem levels were 158.1 mg/L (standard deviation [SD] ± 62.9) and 29.4 mg/L (SD ± 15.9), respectively. The mean dialysate meropenem level was at its minimum of 32.6 mg/L (SD ± 19.1) at 24 hours. Throughout the period, the dialysate meropenem levels exceeded the minimal inhibitory concentration of the pathogenic resistance organism (> 8 mg/L). Four patients responded to the treatment, whereas one developed treatment failure from fungal peritonitis.
Conclusion
An IP meropenem loading of 500 mg, followed by 125 mg/L every 6 hours, provided an adequate dialysate meropenem concentration and is an effective treatment for PD related peritonitis.
Trial registration
Thai Clinical Trials Registry ( TCTR20191121002 ) with date of first registration at 21/11/2019 (retrospectively registered).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Thatsaphan Srithongkul, Pornpan Koomanachai
Zitieren
APA
Srithongkul, T., Raksasuk, S., Techajongnumchai, B., Sritippayawan, S., & Koomanachai, P. (2025). Dialysate and plasma meropenem concentrations in continuous intraperitoneal regimen during peritoneal-dialysis-related peritonitis. PLOS ONE. https://doi.org/10.1371/journal.pone.0312160
Vancouver
Srithongkul T, Raksasuk S, Techajongnumchai B, Sritippayawan S, Koomanachai P. Dialysate and plasma meropenem concentrations in continuous intraperitoneal regimen during peritoneal-dialysis-related peritonitis. PLOS ONE. 2025. doi:10.1371/journal.pone.0312160
BibTeX
@article{Srithongkul2025,
author = {Srithongkul, Thatsaphan and Raksasuk, Sukit and Techajongnumchai, Bulaporn and Sritippayawan, Suchai and Koomanachai, Pornpan},
title = {Dialysate and plasma meropenem concentrations in continuous intraperitoneal regimen during peritoneal-dialysis-related peritonitis},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0312160}
}
EUVIMED